Classification, Diagnosis, and Management of Cholangiocarcinoma

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 1, 2013, Pages

  Razumilava, Nataliya ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Distal Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; CISPLATIN; CORTICOSTEROID; CYTOKERATIN 19; CYTOKERATIN 7; GEMCITABINE; IMMUNOGLOBULIN G4; NATURAL KILLER CELL RECEPTOR NKG2D;

ABDOMINAL DISCOMFORT; ANOREXIA; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BILIARY STENT; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FLUORESCENCE; HEPATITIS; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JAUNDICE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER METASTASIS; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALAISE; META ANALYSIS (TOPIC); MULTIDETECTOR COMPUTED TOMOGRAPHY; NAUSEA; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PANCREAS CANCER; PORTAL VEIN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PROCTOCOLECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR BIOPSY; WEIGHT REDUCTION;

EID: 84870879515     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.09.009     Document Type: Review

References (81)

1. Blechacz B., Komuta M., Roskams T., et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011, 8:512-522.
2. Everhart J.E., Ruhl C.E. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology 2009, 136:1134-1144.
3. Khan S.A., Emadossadaty S., Ladep N.G., et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol 2012, 56:848-854.
4. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245:755-762.
5. Kipp B.R., Voss J.S., Kerr S.E., et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol 2012, 43:1552-1558.
6. Tyson G.L., El-Serag H.B. Risk factors for cholangiocarcinoma. Hepatology 2011, 54:173-184.
7. Lee T.Y., Lee S.S., Jung S.W., et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008, 103:1716-1720.
8. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007, 5:1221-1228.
9. Söreide K., Körner H., Havnen J., et al. Bile duct cysts in adults. Br J Surg 2004, 91:1538-1548.
10. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24:115-125.
11. Nakanuma Y., Sato Y., Harada K., et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010, 2:419-427.
12. Huang M.H., Chen C.H., Yen C.M., et al. Relation of hepatolithiasis to helminthic infestation. J Gastroenterol Hepatol 2005, 20:141-146.
13. Donato F., Gelatti U., Tagger A., et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001, 12:959-964.
14. Shaib Y.H., El-Serag H.B., Davila J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128:620-626.
15. Welzel T.M., Mellemkjaer L., Gloria G., et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007, 120:638-641.
16. Tocchi A., Mazzoni G., Liotta G., et al. Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients. Ann Surg 2001, 234:210-214.
17. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
18. Farrant J.M., Hayllar K.M., Wilkinson M.L., et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991, 100:1710-1717.
19. Helzberg J.H., Peterson J.M., Boyer J.L. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1887, 92:1869-1875.
20. Kornfeld D., Ekbom A., Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997, 32:1042-1045.
21. Razumilava N., Gores G.J., Lindor K.D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011, 54:1842-1852.
22. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
23. Yamamoto M., Takasaki K., Nakano M., et al. Minute nodular intrahepatic cholangiocarcinoma. Cancer 1998, 82:2145-2149.
24. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003, 10:288-291.
25. Komuta M., Govaere O., Vandecaveye V., et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 2012, 55:1876-1888.
26. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006, 25:3818-3822.
27. Fan B., Malato Y., Calvisi D.F., et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012, 122:2911-2915.
28. Rimola J., Forner A., Reig M., et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009, 50:791-798.
29. Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford) 2008, 10:106-109.
30. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004, 8:90-97.
31. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006, 45:43-50.
32. Lan B.Y., Kwee S.A., Wong L.L. Positron emission tomography in hepatobiliary and pancreatic malignancies: a review. Am J Surg 2012, 204:232-241.
33. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:204-207.
34. Charatcharoenwitthaya P., Enders F.B., Halling K.C., et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106-1117.
35. Nehls O., Gregor M., Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004, 24:139-154.
36. Durnez A., Verslype C., Nevens F., et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006, 49:138-151.
37. Sapisochin G., Fidelman N., Roberts J.P., et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011, 17:934-942.
38. Uenishi T., Kubo S., Yamamoto T., et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003, 94:851-857.
39. Endo I., Gonen M., Yopp A.C., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008, 248:84-96.
40. Li Y.Y., Li H., Lv P., et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment. J Gastrointest Surg 2011, 15:608-613.
41. Rana A., Hong J.C. Orthotopic liver transplantation in combination with neoadjuvant therapy: a new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012, 28:258-265.
42. Goodman Z.D., Ishak K.G., Langloss J.M., et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985, 55:124-135.
43. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362:1273-1281.
44. Horgan A.M., Amir E., Walter T., et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012, 30:1934-1940.
45. Andersen J.B., Spee B., Blechacz B.R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012, 142:1021-1031.e1015.
46. Kiefer M.V., Albert M., McNally M., et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011, 117:1498-1505.
47. Hoffmann R.T., Paprottka P.M., Schön A., et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012, 35:105-116.
48. Kim J.H., Won H.J., Shin Y.M., et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011, 196:W205-W209.
49. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
50. Nagorney D.M., Donohue J.H., Farnell M.B., et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993, 128:871-877. discussion, 877-879.
51. Deoliveira M.L., Schulick R.D., Nimura Y., et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011, 53:1363-1371.
52. Bismuth H., Corlette M.B. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975, 140:170-178.
53. Heimbach J.K., Sanchez W., Rosen C.B., et al. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB (Oxford) 2011, 13:356-360. 2011.
54. Levy M.J., Heimbach J.K., Gores G.J. Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol 2012, 28:244-252.
55. Barr Fritcher E.G., Kipp B.R., Slezak J.M., et al. Correlating routine cytology, quantitative nuclear morphometry by digital image analysis, and genetic alterations by fluorescence in situ hybridization to assess the sensitivity of cytology for detecting pancreatobiliary tract malignancy. Am J Clin Pathol 2007, 128:272-279.
56. Gonda T.A., Glick M.P., Sethi A., et al. Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures. Gastrointest Endosc 2012, 75:74-79.
57. Fritcher E.G., Kipp B.R., Halling K.C., et al. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009, 136:2180-2186.
58. Kipp B.R., Stadheim L.M., Halling S.A., et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004, 99:1675-1681.
59. Moreno Luna L.E., Kipp B., Halling K.C., et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006, 131:1064-1072.
60. Bangarulingam S.Y., Bjornsson E., Enders F., et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010, 51:174-180.
61. Ghazale A., Chari S.T., Zhang L., et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008, 134:706-715.
62. Stone J.H., Zen Y., Deshpande V. IgG4-related disease. N Engl J Med 2012, 366:539-551.
63. Baskin-Bey E.S., Devarbhavi H.C., Nagorney D.M., et al. Idiopathic benign biliary strictures in surgically resected patients with presumed cholangiocarcinoma. HPB (Oxford) 2005, 7:283-288.
64. Rosen C.B., Heimbach J.K., Gores G.J. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008, 10:186-189.
65. Nagorney D.M., Kendrick M.L. Hepatic resection in the treatment of hilar cholangiocarcinoma. Adv Surg 2006, 40:159-171.
66. van der Gaag N.A., Rauws E.A., van Eijck C.H., et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010, 362:129-137.
67. Murad S.D., Kim W.R., Harnois D.M., et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012, 143:88-98.
68. Hong J.C., Jones C.M., Duffy J.P., et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011, 146:683-689.
69. Darwish Murad S., Kim W.R., Therneau T., et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012, 56:972-981.
70. Weston B.R., Ross W.A., Wolff R.A., et al. Rate of bilirubin regression after stenting in malignant biliary obstruction for the initiation of chemotherapy: how soon should we repeat endoscopic retrograde cholangiopancreatography?. Cancer 2008, 112:2417-2423.
71. Vienne A., Hobeika E., Gouya H., et al. Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 2010, 72:728-735.
72. Deviere J., Baize M., de Toeuf J., et al. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. Gastrointest Endosc 1988, 34:95-101.
73. Chang W.H., Kortan P., Haber G.B. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998, 47:354-362.
74. Soderlund C., Linder S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 2006, 63:986-995.
75. Raju R.P., Jaganmohan S.R., Ross W.A., et al. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci 2011, 56:1557-1564.
76. Yeoh K.G., Zimmerman M.J., Cunningham J.T., et al. Comparative costs of metal versus plastic biliary stent strategies for malignant obstructive jaundice by decision analysis. Gastrointest Endosc 1999, 49:466-471.
77. Kullman E., Frozanpor F., Söderlund C., et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010, 72:915-923.
78. Krokidis M., Fanelli F., Orgera G., et al. Percutaneous treatment of malignant jaundice due to extrahepatic cholangiocarcinoma: covered Viabil stent versus uncovered Wallstents. Cardiovasc Intervent Radiol 2010, 33:97-106.
79. Isayama H., Komatsu Y., Tsujino T., et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004, 53:729-734.
80. Kahaleh M., Tokar J., Conaway M.R., et al. Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc 2005, 61:528-533.
81. Siddiqui A.A., Mehendiratta V., Jackson W., et al. Identification of cholangiocarcinoma by using the spyglass spyscope system for peroral cholangioscopy and biopsy collection. Clin Gastroenterol Hepatol 2012, 10:466-471.